Preclinical and Clinical Studies with Selective Reversible Direct P2Y₁₂ Antagonists

 

 Buy Article Permissions and Reprints

ABSTRACT

An important role for adenosine diphosphate (ADP)-induced platelet activation and aggregation was proposed more than 40 years ago. The clinical use of clopidogrel, a prodrug of an irreversible P2Y₁₂ antagonist, has further proved the relevance of inhibiting signaling via the platelet-specific P2Y₁₂ ADP receptor in the prevention of cardiovascular events. Pharmacological studies at AstraZeneca R&D Charnwood have identified direct, selective, and competitive P2Y₁₂ antagonists, including cangrelor (also known as AR-C69931MX), which is suitable for intravenous administration, and AZD6140, which is suitable for oral administration. In preclinical use, these compounds predictably and effectively inhibited platelet aggregation without significant increases in bleeding time. In clinical use, these compounds may have significant advantages over current antiplatelet agents. This article summarizes preclinical and clinical data on cangrelor and AZD6140 and discusses the potential of these compounds as novel antiplatelet therapies.

REFERENCES

• 1 Gaarder A, Jonson J, Laland S, Lellem A, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human platelets.  Nature. 1961;  192 531-532
  PubMedGoogle Scholar
• 2 Burnstock G, King B. Numbering of cloned P2 receptors.  Drug Dev Res. 1996;  38 67-71
  CrossrefPubMedGoogle Scholar
• 3 Fagura M S, Dainty I A, McKay G D et al.. P2Y₁-receptors in human platelets which are pharmacologically distinct from P2YADP-receptors.  Br J Pharmacol. 1998;  124 157-164
  CrossrefPubMedGoogle Scholar
• 4 Hollopeter G, Jantzen H M, Vincent D et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
  CrossrefPubMedGoogle Scholar
• 5 McFarlane D, Mills D. The effect of ATP on platelets: evidence against the central role of released ADP in primary aggregation.  Blood. 1975;  46 309-320
  PubMedGoogle Scholar
• 6 Gordon J. Extracellular ATP: effects, sources and fate.  Biochem J. 1986;  233 309-319
  PubMedGoogle Scholar
• 7 Cusack N, Hourani S. Adenosine 5′-diphosphate antagonists and human platelets: no evidence that that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors.  Br J Pharmacol. 1982;  76 221-227
  PubMedGoogle Scholar
• 8 Cusack N, Hourani S. Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5′-monophosphate and adenosine 5′-triphosphate of human platelet aggregation induced by adenosine 5′-diphosphate.  Br J Pharmacol. 1982;  75 397-400
  PubMedGoogle Scholar
• 9 Welford L, Cusack N, Hourani S. ATP analogues and the guinea-pig Taenia coli : a comparison of the structure-activity relationships of ectonucleotidases with those of the P2-purinoceptor.  Eur J Pharmacol. 1986;  129 217-224
  CrossrefPubMedGoogle Scholar
• 10 Humphries R G, Tomlinson W, Ingall A H, Cage P A, Leff P. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.  Br J Pharmacol. 1994;  113 1057-1063
  PubMedGoogle Scholar
• 11 Humphries R G, Tomlinson W, Clegg J A et al.. Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo.  Br J Pharmacol. 1995;  115 1110-1116
  PubMedGoogle Scholar
• 12 Ingall A H, Dixon J, Bailey A et al.. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.  J Med Chem. 1999;  42 213-220
  CrossrefPubMedGoogle Scholar
• 13 Communi D, Robaye B, Boeynaems J M. Pharmacological characterization of the human P2Y₁₁ receptor.  Br J Pharmacol. 1999;  128 1199-1206
  CrossrefPubMedGoogle Scholar
• 14 Marteau F, Le Poul E, Communi D et al.. Pharmacological characterization of the human P2Y₁₃ receptor.  Mol Pharmacol. 2003;  64 104-112
  CrossrefPubMedGoogle Scholar
• 15 Storey R F, Oldroyd K G, Wilcox R G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.  Thromb Haemost. 2001;  85 401-407
  PubMedGoogle Scholar
• 16 Fox S, Burgess-Wilson M, Heptinstall S, Mitchell J. Platelet aggregation in whole blood determined using the Ultra-Flow 100 platelet counter.  Thromb Haemost. 1982;  48 327-329
  PubMedGoogle Scholar
• 17 Tomlinson W, Cusworth E A, Midha A et al.. Characterization of the P2T receptor antagonist properties of AR-C69931MX in human washed platelets in vitro.  Haematologica. 2000;  85 95-96 , (abst)
  PubMedGoogle Scholar
• 18 Maayani S, Tagliente T M, Schwarz T et al.. The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes.  Platelets. 2001;  12 83-93
  CrossrefPubMedGoogle Scholar
• 19 Lova P, Paganini S, Hirsch E et al.. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B.  J Biol Chem. 2003;  278 131-138
  PubMedGoogle Scholar
• 20 Lova P, Paganini S, Sinigaglia F, Balduini C, Torti M. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets.  J Biol Chem. 2002;  277 12009-12015
  CrossrefPubMedGoogle Scholar
• 21 Jin J, Tomlinson W, Kirk I P et al.. The C6-2B glioma cell P2YAC receptor is pharmacologically and molecularly identical to the platelet P2Y12 receptor.  Br J Pharmacol. 2001;  133 521-528
  CrossrefPubMedGoogle Scholar
• 22 Jagroop I A, Burnstock G, Mikhailidis D P. Both the ADP receptors P2Y1 and P2Y₁₂, play a role in controlling shape change in human platelets.  Platelets. 2003;  14 15-20
  CrossrefPubMedGoogle Scholar
• 23 Goto S, Tamura N, Eto K, Ikeda Y, Handa S. Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate.  Circulation. 2002;  105 2531-2536
  CrossrefPubMedGoogle Scholar
• 24 Nylander S, Mattsson C, Ramstrom S, Lindahl T. The relative importance of the ADP receptors, P2Y₁₂ and P2Y₁, in thrombin-induced platelet activation.  Thromb Res. 2003;  111 65-73
  CrossrefPubMedGoogle Scholar
• 25 Jung S M, Moroi M. Platelet collagen receptor integrin alpha2beta1 activation involves differential participation of ADP-receptor subtypes P2Y1 and P2Y12 but not intracellular calcium change.  Eur J Biochem. 2001;  268 3513-3522
  CrossrefPubMedGoogle Scholar
• 26 Ishii-Watabe A, Uchida E, Mizuguchi H, Hayakawa T. On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP.  Biochem Pharmacol. 2000;  59 1345-1355
  CrossrefPubMedGoogle Scholar
• 27 Leff P, Robertson M J, Humphries R G. The role of ADP in thrombosis and the therapeutic potential of P2T-receptor antagonists as novel antithrombotic agents. In: Jacobson A, Jarvis MF Purinergic Approaches in Experimental Therapeutics New York; Wiley-Liss 1997: 203-216
  Google Scholar
• 28 Humphries R G, Nicol A K, Tomlinson W et al.. Effect of the novel P2T receptor antagonist, AR-C69931MX, on thrombosis and haemostasis in the dog: comparison with GPIIb/IIIa antagonists.  Haematologica. 2000;  85 91-92 , (abst)
  PubMedGoogle Scholar
• 29 Huang J, Driscoll E M, Gonzales M L, Park A M, Lucchesi B R. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model1.  J Pharmacol Exp Ther. 2000;  295 492-499
  PubMedGoogle Scholar
• 30 van Gestel M A, Heemskerk J W, Slaaf D W et al.. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.  Arterioscler Thromb Vasc Biol. 2003;  23 518-523
  PubMedGoogle Scholar
• 31 Wang K, Zhou X, Zhou Z et al.. Blockade of the platelet P2Y₁₂ receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.  Arterioscler Thromb Vasc Biol. 2003;  23 357-362
  PubMedGoogle Scholar
• 32 Nurden A T, Nurden P. Advantages of fast-acting ADP receptor blockade in ischemic heart disease.  Arterioscler Thromb Vasc Biol. 2003;  23 158-159
  PubMedGoogle Scholar
• 33 Storey R F. Clinical experience with antithrombotic drugs acting on purine receptor pathways.  Drug Dev Res. 2001;  52 202-212
  CrossrefPubMedGoogle Scholar
• 34 Nassim M A, Sanderson J B, Clarke C et al.. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers.  J Am Coll Cardiol. 1999;  33 225 , (abst)
  PubMedGoogle Scholar
• 35 Rao A K, Pratt C, Berke A et al.. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.  J Am Coll Cardiol. 1988;  11 1-11
  CrossrefPubMedGoogle Scholar
• 36 Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction.  Clin Ther. 2002;  24 752-765
  CrossrefPubMedGoogle Scholar
• 37 Weaver W D, Becker R, Harrington R A et al.. Safety and efficacy of a novel direct P2T platelet receptor antagonist, AR-C69931MX, in patients undergoing percutaneous coronary intervention.  Eur Heart J. 2000;  21 382 , (abst)
  CrossrefPubMedGoogle Scholar
• 38 Greenbaum A, Ohman E, Gibson M et al.. Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction.  J Am Coll Cardiol. 2002;  39 281A , (abst)
  PubMedGoogle Scholar
• 39 Gurbel P A, Bliden K P, Hiatt B L, O'Connor C M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.  Circulation. 2003;  107 2908-2913
  CrossrefPubMedGoogle Scholar
• 40 Jaremo P, Lundahl T L, Fransson S G, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel.  J Intern Med. 2002;  252 233-238
  CrossrefPubMedGoogle Scholar
• 41 Muller I, Besta F, Schulz C et al.. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.  Thromb Haemost. 2003;  89 783-787
  PubMedGoogle Scholar
• 42 Gurbel P A, Bliden K P. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened reactivity.  Platelets. 2003;  14 481-483
  CrossrefPubMedGoogle Scholar
• 43 Gurbel P A, Bliden K P. Durability of platelet inhibition by clopidogrel.  Am J Cardiol. 2003;  91 1123-1125
  CrossrefPubMedGoogle Scholar
• 44 Lau W C, Gurbel P A, Watkins P B et al.. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.  Circulation. 2004;  109 166-171
  CrossrefPubMedGoogle Scholar
• 45 Lau W C, Waskell L A, Watkins P B et al.. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation-a new drug-drug interaction.  Circulation. 2003;  107 32-37
  CrossrefPubMedGoogle Scholar
• 46 Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study.  Eur Heart J. 2003;  24 1744-1749
  CrossrefPubMedGoogle Scholar
• 47 Muller I, Besta F, Schulz C et al.. Effects of statins on platelet inhibition by a high loading dose of clopidogrel.  Circulation. 2003;  108 2195-2197
  CrossrefPubMedGoogle Scholar
• 48 Jarvis G E, Nassim M A, Humphries R G et al.. Clopidogrel produces incomplete inhibition of [33P]-2MeSADP binding to human platelets and less inhibition of ADP-induced platelet aggregation than the P2T antagonist AR-C69931MX.  Haematologica. 2000;  85 92-93 , (abst)
  PubMedGoogle Scholar
• 49 Storey R F, Wilcox R G, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.  Platelets. 2002;  13 407-413(abs)
  CrossrefPubMedGoogle Scholar
• 50 Beham M W, Fox S, Sanderson H, Storey R, Heptinstall S. Effect of clopidogrel on procoagulant activity in acute coronary syndromes: evidence for incomplete P2Y₁₂ receptor blockade.  Circulation. 2002;  106 II-149-II-150 , (abst)
  PubMedGoogle Scholar
• 51 Humphries R G. Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials.  Haematologica. 2000;  85 66-72
  PubMedGoogle Scholar

 Dr.
Johan J.J van Giezen

AstraZeneca R&D Mölndal, Department of Integrative Pharmacology

Pepparedsleden 1, S-431 83 Mölndal, Sweden

Email: Hans.vanGiezen@astrazeneca.com